Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
Status:
Active, not recruiting
Trial end date:
2021-12-13
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well apalutamide works in treating patients with prostate
cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer
cells. Hormone therapy using androgen receptor antagonist apalutamide may fight prostate
cancer by blocking the use of testosterone by the tumor cells.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
Janssen Scientific Affairs, LLC National Cancer Institute (NCI)